Fred Alger Management Invests $30.82M in Exact Sciences

Hedge fund takes major stake in medical research company

Mar. 16, 2026 at 10:18am

Got story updates? Submit your updates here. ›

Fred Alger Management LLC, a prominent investment firm, has acquired a new stake in Exact Sciences Corporation (NASDAQ:EXAS), purchasing 563,292 shares valued at approximately $30.82 million. This represents a 0.30% ownership stake in the medical research company, known for its Cologuard colorectal cancer screening test.

Why it matters

Exact Sciences has been a focus of investor interest due to the growth potential of its Cologuard test, which aims to improve colorectal cancer screening adherence. The investment by Fred Alger Management, a respected hedge fund, signals confidence in the company's long-term prospects.

The details

According to a recent 13F filing with the SEC, Fred Alger Management acquired the new stake in Exact Sciences during the third quarter. The firm now owns 0.30% of the company's outstanding shares. Exact Sciences has seen its stock price rise significantly in recent months, driven by the continued adoption of Cologuard and the company's broader diagnostic pipeline.

  • The 13F filing was submitted in the 3rd quarter of the year.
  • Fred Alger Management acquired the stake in Exact Sciences during that same 3rd quarter period.

The players

Fred Alger Management LLC

A prominent investment management firm based in New York City that focuses on growth-oriented equity strategies.

Exact Sciences Corporation

A medical research company headquartered in Madison, Wisconsin, known for its Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

The investment by Fred Alger Management in Exact Sciences underscores the market's confidence in the company's diagnostic products, particularly the Cologuard test, and its potential to drive growth in the medical research sector.